Form 4: Clover Health CEO Sells Shares for Tax Obligations

Clover Health's CEO, Conrad Wai, disposed of 98,411 Class A Common Stock shares to cover tax obligations related to RSU vesting.

Summary

• Conrad Wai, CEO of Counterpart Health (Clover Health Investments, Corp.), reported a disposition of Class A Common Stock.
• The transaction involved 98,411 shares, sold at a price of $2.7 per share.
• This disposition was to cover tax obligations arising from the vesting of Restricted Stock Units (RSUs).
• 6.25% of the original time-based RSUs, granted on March 14, 2022, vested on December 14, 2025.
• Following the transaction, Wai beneficially owns 1,051,674 shares directly and 1,610,482 shares indirectly through a trust.
• The transaction was executed under a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: The transaction is a standard tax-related disposition of shares following RSU vesting, executed under a pre-arranged 10b5-1 plan. It does not reflect a discretionary sale by the insider or indicate any new positive or negative developments for the company.

Positives

• The transaction was non-discretionary, executed to cover tax obligations upon RSU vesting, not a voluntary sale of shares.
• The executive continues to hold a substantial number of shares, totaling 2,662,156 shares (direct and indirect).
• The vesting of RSUs implies the executive's continued service to the company.

Negatives

• The disposition of 98,411 shares reduces the direct beneficial ownership of the reporting person.
• The transaction price of $2.7 per share is noted.

Risks

• NA

Future Outlook

Remaining Restricted Stock Units (RSUs) are scheduled to vest quarterly in equal installments of 6.25%, with a final vesting date occurring on March 14, 2026, contingent upon the reporting person's continued service.

Management Comments

• NA

Industry Context

NA

Comparison to Industry Standards

• NA

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: A slight reduction in direct insider ownership, but the overall beneficial ownership remains substantial. The non-discretionary nature of the sale mitigates potential negative perceptions.
• Employees: The RSU vesting structure is part of executive compensation, which is a standard practice.

Next Steps

• Remaining RSUs will vest quarterly in equal installments of 6.25% until March 14, 2026, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary sale of shares by an executive to cover tax obligations upon RSU vesting, executed under a pre-arranged 10b5-1 plan. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The executive retains a significant stake in the company. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present a catalyst for a change in investment thesis.

Keywords

Clover Health, CLOV, Form 4, insider trading, stock sale, RSU vesting, tax obligations, beneficial ownership, executive compensation